<DOC>
	<DOCNO>NCT00002719</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Colony-stimulating factor G-CSF may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover chemotherapy radiation therapy . Combining one drug give drug different way may kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without G-CSF treat old patient acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without G-CSF Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess role granulocyte colony-stimulating factor give and/or remission induction MICE ( mitoxantrone/cytarabine/etoposide ) elderly patient acute myelogenous leukemia ( AML ) . II . Compare complete remission ( CR ) rate survival patient treat nearly equivalent dos oral vs. intravenous mini-ICE ( idarubicin/cytarabine/etoposide ) consolidation therapy give outpatient basis . III . Evaluate feasibility second intensive consolidation regimen consist BAVC ( carmustine/amsacrine/etoposide/cytarabine ) follow autologous stem cell support patient age 71 CR good performance status . OUTLINE : Randomized study . All patient randomly assign Arms IA ID Induction . Patients achieve CR adequate organ function performance status randomly assign Arm IIA IIB Consolidation . At select center , patient CR first Consolidation course age 71 good clinical condition treat Regimen A ( lieu second Consolidation course ) . The following acronym use : AMSA Amsacrine , NSC-249992 ARA-C Cytarabine , NSC-63878 BAVC BCNU/AMSA/VP-16/ARA-C BCNU Carmustine , NSC-409962 DHAD Mitoxantrone , NSC-301739 G-CSF Granulocyte Colony-Stimulating Factor ( Rhone-Poulenc Rorer ) IDA Idarubicin , NSC-256439 MICE DHAD/ARA-C/VP-16 Mini-ICE IDA/ARA-C/VP-16 PBSC Peripheral Blood Stem Cells VP-16 Etoposide , NSC-141540 INDUCTION : Arm IA : 3-Drug Combination Chemotherapy . MICE . Arm IB : 3-Drug Combination Chemotherapy plus Hematologic Toxicity Attenuation . MICE ; plus G-CSF . G-CSF chemotherapy . Arm IC : 3-Drug Combination Chemotherapy plus Hematologic Toxicity Attenuation . MICE ; plus G-CSF . G-CSF chemotherapy . Arm ID : 3-Drug Combination Chemotherapy plus Hematologic Toxicity Attenuation . MICE ; plus G-CSF . G-CSF chemotherapy . CONSOLIDATION : Arm IIA : 3-Drug Combination Chemotherapy . Mini-ICE . Intravenous IDA/VP-16/ARA-C . Arm IIB : 3-Drug Combination Chemotherapy . Mini-ICE . Oral IDA/VP-16 + subcutaneous ARA-C . Regimen A : Stem Cell Mobilization follow 4-Drug Combination Myeloablative Chemotherapy Stem Cell Rescue . G-CSF ; follow BAVC ; PBSC . PROJECTED ACCRUAL : 500 patient randomized Induction , anticipate 238 patient randomized Consolidation . If interim analysis survival short Regimen A , regimen close .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Amsacrine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myeloblastic leukemia ( AML ) At least 30 % blast cell bone marrow smear Secondary AML eligible , follow : Secondary myelodysplastic syndrome ( myeloproliferative disease ) Secondary cure Hodgkin 's disease cure malignancy Secondary alkylating agent radiation reason Acute promyelocytic leukemia ( M3 ) refer collaborative Gruppo Italiano Malattie Ematologiche Maligne dell'AdultoEORTC protocol ( EORTC06952 ) No blast crisis chronic myeloid leukemia PATIENT CHARACTERISTICS : Age : 61 80 Performance status : WHO 02 Life expectancy : No marked impairment disease AML Hematopoietic : Not applicable Hepatic : Bilirubin le 2 x ULN Renal : Creatinine le 2 x ULN Cardiovascular : LVEF least 50 % No severe cardiac disease Pulmonary : No severe pulmonary disease Other : HIV seronegative ( test ) No uncontrolled infection No severe neurologic , metabolic , psychiatric disease No concomitant disease preclude protocol therapy No progressive malignant disease PRIOR CONCURRENT THERAPY : No prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>neutropenia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>